Meet Inspiring Speakers and Experts at our 3000+ Global Conference Series Events with over 1000+ Conferences, 1000+ Symposiums
and 1000+ Workshops on Medical, Pharma, Engineering, Science, Technology and Business.

Explore and learn more about Conference Series : World's leading Event Organizer

Back

Mariola Napiórkowska

Mariola Napiórkowska

Medical University of Warsaw, Poland

Title: Synthesis and cytotoxic properties of new derivatives of dicarboximides

Biography

Biography: Mariola Napiórkowska

Abstract

The growth rate of the number of cancer cases is enormous and requires intensive research and introduction of new anticancer drugs. Ideally, these new drugs should possess improved pharmacokinetic parameters and high selectivity towards cancer cells providing less negative side effects. The present work describes the synthesis and cytotoxic activity of a large group of new derivatives of dicarboximides. In our previously studies with this group of compounds we have identified several derivatives that presented highest cytotoxicity to leukemia cells, lines K562, HL-60, respectively (IC50* in the range of 1-10µM). On the contrary, these compounds were non-toxic to non-tumor endothelial cells (HUVEC) and tumor adherent cells (HeLa). Taking into account the high activity of evaluated compounds, we decided to continue our work on the field of these derivatives. The main stage of synthetic works was the modification of the structure of dicarboximides in order to obtain  products with improved solubility and bioavailability, while retaining their biological activity. In order to improve the solubility of the compounds hydrophilic groups such as -OH, -NH2, -NH-R were introduced to their structure. Thus we have synthesized 33 new derivatives.  The structures of all new compounds were established by  1HNMR, 13CNMR and HR MS spectra. The obtained compounds were tested for their cytotoxic properties in cervix carcinoma (HeLa), chronic myelogenous leukemia (K562), acute lymphoblastic leukemia (MOLT-4)  and normal endothelial (HUVEC) cells using MTT assay. In these screening studies we have identified 28 compounds that showed toxicity toward both HeLa, K562 and MOLT-4 cell lines.